Bhargava added that when the ICMR weighed the risks and benefits of the drug, it decided that “we should not deny it to our frontline workers and healthcare workers.”
But he stressed that personal protective gear should still be worn.
The previous ICMR guidelines for hydroxychloroquine stated that only asymptomatic healthcare workers caring for suspected or confirmed patients, or household contacts of confirmed patients, could be given the drug.
On Monday, the WHO said it was halting testing of the drug as a COVID-19 treatment after studies questioned its safety, including one that found it actually increased the risk of death.
Under India’s clinical guidelines for coronavirus treatment, hydroxychloroquine can be administered, but only to patients “with severe disease and requiring ICU management”.
India — which accounts for 70 percent of global production of hydroxychloroquine — on Tuesday reported 145,380 cases of the virus including 4,167 deaths.
The country ramped up output of the drug amid increased demand, after Trump pushed for hydroxychloroquine as a potential shield or treatment for the virus.